

Pierre Guyot appointed new President and CEO of Mölnlycke Health Care

Gothenburg, July 10, 2007 – Pierre Guyot, President of the Wound Care Division within Mölnlycke, has been appointed new President and CEO of Mölnlycke Health Care Group, effective July 10, 2007. Pierre will continue to be based in Gothenburg.

Pierre has solid experience from the medical device industry having worked for Boston Scientific, Becton Dickinson and Johnson& Johnson prior to joining Mölnlycke in March 2006.

Pierre will maintain his responsibility for the Wound Care Division until a successor has been appointed.

"John Samuel started as CEO 2 years ago. His key challenge was Mölnlycke's integration with Regent Medical and Medlock Medical. This task is now completed and going forward the company needs a different mix of skills and experiences. We are convinced that Pierre Guyot has the knowledge needed and will successfully run Mölnlycke", stated Gunnar Brock, Chairman of the Board of Mölnlycke Health Care since Investor acquired the company.

The Board of Mölnlycke Health Care

For information contact; Christina Sterner, Communication Director +46 31 722 30 00

Notes to Editors

- Mölnlycke Health Care (Mölnlycke) is a world leading manufacturer of single-use surgical and wound care products and services for the professional health care sector
- Based in Gothenburg, Sweden the company numbers **5,500 employees**
- **24 offices**: 18 in EMEA, 2 in North America and 4 in the Asia Pacific region
- **Plants**: Belgium, Czech Republic, Finland, UK, Malaysia (3), Thailand (2)
- Mölnlycke markets its products worldwide with sales dividing to 80% in EMEA, 17% in North America and 3% in Asia.
- Mölnlycke Health Care started operations as an independent company in 1998 and was acquired from Apax Partners by Investor in January 2007.
- 2005 Sales €742m, 2006 Sales €747m
- 2005 EBITA €161m, 2006 EBITA €198m

Two business divisions

Wound care - develops and manufactures products for chronic and surgical wounds, burns and complementary products in compression therapy and dermatology

- Market dynamics driven by aging population, higher incidence of pressure ulcers and increased home treatment
- Advanced products market growing at approximately 10% annually

- Mölnlycke sales growing at approximately 22% annually led by its patented Safetac® technology
- Global wound care leader with the fastest growing advanced wound healing segment in Europe
- Current brands include Xelma®, Mepore®, Mepilex®, Mepitel®, Tubigrip®, Tubifast®
- Strong pipeline of advanced and active products in R&D
- Wound care has unique products, a high share of voice and market in important geographical regions
- Market size approx €3bn

Surgical – develops and manufactures a wide range of single-use surgical products

- Holds **No.1 market position in EMEA** for single use drapes & staff clothing, powder free gloves, headwear and, in the UK, for surgical scrubs
- Also, No. 1 in the US by value for powder free gloves and surgical scrubs
- In the European market, 37% is still reusable-there is a rising demand for single use products and significant growth opportunities exist
- Market size approx €3bn